AstraZeneca has forged a wide-ranging collaboration with Chinese biotech CSPC Pharma that will focus on the use of artificial intelligence (AI) to find new medicines across a range of diseases.

With the Federal Reserve poised to implement interest rate cuts (albeit fewer than earlier forecasts assumed) and FTC leadership turnover anticipated, there may be broader shifts in how capital is ...